Key regions: Australia, Italy, France, South Korea, Brazil
The Swiss healthcare system is known for its high quality and accessibility, with a strong emphasis on preventive care. This has led to a growing demand for vaccines in Switzerland, as individuals seek to protect themselves and their families from preventable diseases.
Customer preferences: Swiss consumers are increasingly concerned about the safety and efficacy of vaccines, and are willing to pay a premium for high-quality products. They also place a strong emphasis on convenience and accessibility, with many opting for vaccines that can be administered at home or in a pharmacy.
Trends in the market: The vaccines market in Switzerland is growing steadily, driven by an aging population and increasing awareness of the importance of preventive care. There has been a particular focus on vaccines for infectious diseases such as influenza, HPV, and meningococcal disease, as well as travel vaccines for those heading to high-risk areas.
Local special circumstances: Switzerland has a highly decentralized healthcare system, with cantons responsible for the provision and financing of healthcare services. This has led to variations in vaccine coverage and access across the country, with some cantons offering more comprehensive vaccination programs than others.
Underlying macroeconomic factors: Switzerland has a strong economy and high levels of healthcare spending, which has helped to support the growth of the vaccines market. However, rising healthcare costs and an aging population are putting pressure on the system, which may lead to changes in the way vaccines are financed and delivered in the future. Additionally, Switzerland's position as a global hub for pharmaceuticals and life sciences has attracted significant investment in research and development, which may lead to new and innovative vaccines in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
